BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 6934003)

  • 1. Absorption of methotrexate under standardized conditions in children with acute lymphoblastic leukaemia.
    Pinkerton CR; Welshman SG; Dempsey SI; Bridges JM; Glasgow JF
    Br J Cancer; 1980 Oct; 42(4):613-5. PubMed ID: 6934003
    [No Abstract]   [Full Text] [Related]  

  • 2. Enterotoxic effect of methotrexate: does it influence the drug's absorption in children with acute lymphoblastic leukaemia?
    Pinkerton CR; Glasgow JF; Bridges JM; Welshman SG
    Br Med J (Clin Res Ed); 1981 Apr; 282(6272):1276-7. PubMed ID: 6784815
    [No Abstract]   [Full Text] [Related]  

  • 3. Modification of oral methotrexate absorption in children with leukemia.
    Mahony MJ; Murphy MS; Wadsworth J; Mott MG
    Cancer Chemother Pharmacol; 1984; 12(2):131-3. PubMed ID: 6583027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can food influence the absorption of methotrexate in children with acute lymphoblastic leukaemia?
    Pinkerton CR; Welshman SG; Glasgow JF; Bridges JM
    Lancet; 1980 Nov; 2(8201):944-6. PubMed ID: 6107590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small intestinal transit time affects methotrexate absorption in children with acute lymphoblastic leukemia.
    Pearson AD; Craft AW; Eastham EJ; Aherne GW; Littleton P; Pearson GL; Campbell AN
    Cancer Chemother Pharmacol; 1985; 14(3):211-5. PubMed ID: 3858014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methotrexate absorption in children with acute lymphoblastic leukemia.
    Craft AW; Rankin A; Aherne W
    Cancer Treat Rep; 1981; 65 Suppl 1():77-81. PubMed ID: 6948609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of co-trimoxazole on methotrexate pharmacokinetics in children with acute lymphoblastic leukemia.
    Beach BJ; Woods WG; Howell SB
    Am J Pediatr Hematol Oncol; 1981; 3(2):115-9. PubMed ID: 6975580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia.
    Pinkerton CR; Welshman SG; Kelly JG; Shanks RG; Bridges JM
    Cancer Chemother Pharmacol; 1982 Dec; 10(1):36-9. PubMed ID: 6961972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic significance of systemic clearance of methotrexate in acute lymphoid leukemia in childhood].
    Borsi J; Révész T; Schuler D
    Orv Hetil; 1986 Feb; 127(8):439-42. PubMed ID: 3456552
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics of oral and intramuscular methotrexate in children with acute lymphoblastic leukaemia.
    Pearson AD; Mills S; Amineddine HA; Long DR; Craft AW; Chessells JM
    Cancer Chemother Pharmacol; 1987; 20(3):243-7. PubMed ID: 3315283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate-induced malabsorption in children with acute lymphoblastic leukaemia.
    Craft AW; Kay H; Lawson DN; McElwain TJ
    Br Med J; 1977 Dec; 2(6101):1511-2. PubMed ID: 271033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral methotrexate is as effective as intramuscular in maintenance therapy of acute lymphoblastic leukaemia.
    Chessells JM; Leiper AD; Tiedemann K; Hardisty RM; Richards S
    Arch Dis Child; 1987 Feb; 62(2):172-6. PubMed ID: 3469936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small bowel function in acute lymphoblastic leukaemia.
    Pearson AD; Craft AW; Pledger JV; Eastham EJ; Laker MF; Pearson GL
    Arch Dis Child; 1984 May; 59(5):460-5. PubMed ID: 6428327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic importance of systemic clearance of methotrexate in childhood acute lymphoblastic leukemia.
    Borsi JD; Revesz T; Schuler D
    Cancer Chemother Pharmacol; 1987; 19(3):261-4. PubMed ID: 3472677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The treatment of childhood acute lymphoblastic leukemia based on the pharmacokinetics of methotrexate in serum and cerebrospinal fluid.
    Muchi H; Ijima H; Karube T
    Nihon Ketsueki Gakkai Zasshi; 1985 Sep; 48(6):1397-408. PubMed ID: 3867213
    [No Abstract]   [Full Text] [Related]  

  • 16. A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia.
    Borsi JD; Moe PJ
    Cancer; 1987 Jul; 60(1):5-13. PubMed ID: 3472638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of intermediate dose methotrexate in patients of non-Hodgkin's lymphoma and acute lymphocytic leukaemia.
    Gadgil SD; Damle SR; Shetty PA; Jussawalla DJ
    Indian J Cancer; 1980 Sep; 17(3):176-8. PubMed ID: 6936382
    [No Abstract]   [Full Text] [Related]  

  • 18. Small bowel enterocyte abnormalities caused by methotrexate treatment in acute lymphoblastic leukaemia of childhood.
    Gwavava NJ; Pinkerton CR; Glasgow JF; Sloan JM; Bridges JM
    J Clin Pathol; 1981 Jul; 34(7):790-5. PubMed ID: 6943149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Massive dose methotrexate with citrovorum factor rescue: MTX-pharmacokinetics, excretion pattern, and techniques for safety administration (author's transl)].
    Sasaki K; Fujimoto T
    Nihon Gan Chiryo Gakkai Shi; 1979 Oct; 14(6):988-96. PubMed ID: 317293
    [No Abstract]   [Full Text] [Related]  

  • 20. Jejunal crypt cell abnormalities associated with methotrexate treatment in children with acute lymphoblastic leukaemia.
    Pinkerton CR; Cameron CH; Sloan JM; Glasgow JF; Gwevava NJ
    J Clin Pathol; 1982 Nov; 35(11):1272-7. PubMed ID: 6958682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.